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Abstract
Background: Spain has dramatically increased the number of controlled circulatory death donors (cDCD). The
initial selection criteria for considering cDCD for kidney transplantation (KT) have been expanded progressively, with
practically no limits in donor age during the last years. We aimed to analyze the early clinical outcomes using
expanded (> 65 years) cDCD in comparison with standard ones.
Methods: Observational multicenter study including 19 transplant centers in Spain. We performed a systematic
inclusion in a central database of every KT from expanded cDCD at each participant unit from January-2012 to
January-2017. Surgical procedures and immunosuppressive protocols were based on local practices. Data was
analyzed in the central office using logistic and Cox regression or competitive-risk models for multivariate analysis.
Median time of follow-up was 18.1 months.
Results: 561 KT were performed with kidneys from cDCD, 135 from donors older than 65 years. As expected,
recipients from older cDCD were also older (65.8 (SD 8.8) vs 53.7 (SD 11.4) years; p < 0.001) and with higher
comorbidity. At 1 year, no differences were found amongst older and younger cDCD KT recipients in terms of
serum creatinine (1.6 (SD 0.7) vs 1.5 (SD 0.8) mg/dl; p = 0.29). Non-death censored graft survival was inferior, but
death-censored graft survival was not different (95.5 vs 98.2% respectively; p = 0.481). They also presented a trend
towards higher delayed graft function (55.4 vs 46.7%; p = 0.09) but a similar rate of primary non-function (3.7 vs
3.1%; p = 0.71), and acute rejection (3.0 vs 6.3%; p = 0.135). In the multivariate analysis, in short follow-up, donor age
was not related with worse survival or poor kidney function (eGFR < 30 ml/min).
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Conclusions: The use of kidneys from expanded cDCD is increasing for older and comorbid patients. Short-term
graft outcomes are similar for expanded and standard cDCD, so they constitute a good-enough source of kidneys
to improve the options of KT wait-listed patients.
Keywords: Kidney transplantation, Elderly donors, Donors after circulatory death, Clinical outcomes, Delayed graft
function
Background
Kidney transplantation (KT) from donors after cardiac
death (DCD) might imply poorer graft outcomes, as
circulatory death constitutes an injury to the organs that
may result in lower graft survival [1]. To minimize that,
DCD are only considered for KT if they fit strict criteria,
including younger donor age than donors after brain
death (DBD). In the US, around 50% of expanded
criteria donor (ECD)-DCD kidneys are discarded, com-
pared to 30–40% of ECD-DBD [2]. However, a signifi-
cant number of discarded ECD-DCD kidneys may be
acceptable for KT [2]. In fact, as age of patients listed
for KT is continuously rising [3, 4], DCD age criteria has
also increased in recent years in many countries, espe-
cially in Europe [5–11], where policies are more open to
expand donor pool criteria, in contrast to the US, where
the potential poorer outcomes could lead to a higher
discarded organ rate.
In Spain, improvements in organ procurement and
assessment tools have allowed us to expand donor
acceptance criteria [12]. Particularly, age limits have
been expanding, so that age itself is not usually a signifi-
cant limiting factor. In contrast, more than half of avail-
able kidneys from donors ≥65 years old are discarded in
the US [13], despite their argued benefits in terms of
patient survival, both after brain death [14–16] and after
circulatory death [17], comparing to remain on dialysis.
However, the increase in donor age is associated with re-
duced graft function as well as limited recipient and
graft survival [18]. Moreover, it has been recently postu-
lated that the use of aged DCD could be detrimental in
elderly recipients [10, 11].
In 2012, Spain developed a strategy to encourage the
use of controlled DCD (cDCD) for transplantation, a
modality less used in our environment because of the
high rate of brain-death donation [19]. That resulted in
a dramatic increase in cDCD transplantation, from 1.4%
of the total donors in 2012 to 18% in 2016 [20]. The
same year, GEODAS working group was created with
the purposes of: 1) collecting data regarding KT from
cDCD; and 2) sharing protocols, outcomes analysis and
experiences [21].
As donor age in this modality has also experienced a sub-
stantial change during the last years, we aimed to analyze
the early results obtained with KT from elderly cDCD do-
nors, both in terms of early clinical outcomes – primary
non function (PNF) and delayed graft function (DGF) – as
well as 1st year patient and graft survival, in order to
reassure with the strategy of using these kidneys for aged
recipients or change the policy if needed.
Methods
Observational and multi-center registry, including 19
transplant centers in Spain. Data from all cDCD (Maas-
tricht type III) KT performed from January 2012 to
January 2017 were collected and prospectively recorded
by nephrologists at each center database following the
same structure. For this analysis, a data manager central
office merged anonymous databases in a single one. In-
formed consent for kidney transplantation and local
electronic data management was obtained according to
each center’s Institutional Review Board policy, and a
central research Ethics Committee of H.U. Puerta de
Hierro approved the project. A pre-defined analysis after
the first 500 cDCD KT was performed in order to evalu-
ate the early results obtained with kidneys from donors
over 65 years, and to establish strategy changes if
needed. This age cut-point was chosen based on the
upper limit recommended by the 1st version of Spanish
National Transplant Organization cDCD strategy guides
in 2012 [19]. In Spain, old donors usually allocate into
old recipients, but there are not any pre-established
common strategy between centers, being the finally deci-
sion made by each center. Sample size was estimated for
a 15% difference in DGF incidence rate between groups.
Graft extraction was performed with or without ante-
mortem vascular cannulation, depending on the center.
The immunosuppressive regimen included induction with
rabbit anti-thymocyte globulin (Thymoglobulin®, Sanofi,
France) or basiliximab (Simulect®, Novartis, Swizerland),
and maintenance with steroids as well as the combination
tacrolimus-mycophenolate or tacrolimus-everolimus,
tailored to patient immunological risk and according to
center’s local practice.
Local standardized serum creatinine (colorimetric) and
glomerular filtration rate (GRF) estimated by Modified-
Diet Renal Disease-4 (MDRD-4) formula were recorded
at month 1, 3, 6 and every 6months thereafter. Clinical
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events such as acute rejection, graft loss or patient death
were recorded as they occurred. Delayed graft function
(DGF) was defined as the need of dialysis during the 1st
week after KT.
Statistics
Data are shown as mean and standard deviation or per-
centages and event rates depending on variable nature.
Continuous variables were compared using t-Student
statistics or Wilcoxon’s test if variables were not nor-
mally distributed. Categorical variables were compared
with two-tailed Chi-square statistics. Significance was
considered when p < 0.05. Patient and graft survival was
estimated by Kaplan-Meier curves (log-rank test). Three
statistical models for survival were used to increase the
robustness of the analysis: logistic regression, Cox re-
gression and competing risk regression analyses.
Logistic regression was used to estimate Odds Ratio
(OR) for 1st year cumulative mortality. Uni and multi-
variate Cox regression models were carried out to
estimate hazard ratio (HR) for survival. Backward step
multivariable regression was performed with principal
variable (old vs. young donor), considering as possible
confounders from donor those included in KDPI
(ethnicity, cause of death, serum creatinine > 1.5 mg/dl,
diabetes mellitus, hypertension, etc.). We also included
other potential confounders as recipient age, sex and
comorbidity, cold ischemia time (CIT), human leukocyte
antigen (HLA) mismatches, prior dialysis modality, prior
KT, time on dialysis prior to transplant as well as other
usual risk variables such as serum creatinine or induc-
tion treatment. Variables with p value< 0.1 in the univar-
iate analysis were included in the multivariable
backward modeling process, besides other variables that
were clinically relevant for the outcome. We also used
competitive-risk models for graft and patient survival,
considering graft loss, death and loss to follow-up as
competitive events. Results are shown as sub-Hazard
Ratio (sHR).
On the other hand, we tested multivariate models for
the impact of donor age group on early clinical outcomes:
primary-non-function (PNF, defined as grafts that never
functioned), DGF, poor kidney function at 12months
(defined as eGFR < 30mL/min). Patients with PNF were
excluded for further analyses of other outcomes.
Analysis was performed using Stata v14 (StataCorp
2015, Stata Statistical Software, College Station, TX).
Results
561 KT recipients from cDCD were included in the study.
Of them, 135 received a KT from a cDCD donor > 65
years. Compared to patients that received a KT from a
younger donor, patients that received a KT from cDCD >
65 years were older (65.8 (8.8) years vs 53.7 (11.4) years,
p < 0.001), more frequently females, diabetics (51.4% vs
26.1%, p < 0.001) and with higher percentage of previous
cardiovascular events (20.7% vs 7.8%, p < 0.001). Donor
cause of death was more frequently a stroke. They were
also better HLA matched and received less frequently thy-
moglobulin as induction therapy (Table 1).
Regarding early clinical events, the group that received
a KT from an older cDCD experienced a trend towards
higher rate of DGF, though the difference was not statis-
tically significant (55.4% vs 46.7%, p = 0.09). Neither we
found any difference in PNF or acute rejection rates
(Table 2). When analyzing other potential risk factors
for PNF and DGF through logistic regression models,
CIT longer than 17 h was found to be a risk factor for
PNF (OR 3.25 [1.02–10.33; p = 0.046]), while dialysis vin-
tage longer than 24 months prior to KT conditioned
DGF (OR 3.44 [2.39–4.94; p < 0.001, Table 3).
In terms of graft function, recipients from older do-
nors showed lower eGFR at 1 year, but not statistically
different serum creatinine (1.60 vs 1.51 mg/dl; p = 0.29,
Table 2). In the multivariate analysis, the risk for poor
renal function (1st year eGFR < 30ml/min) associated
with DGF (4.12 [2.07–8.22]; p < 0.001) but not with
donor age (Table 3).
On the other hand, cumulative mortality during 1st
year was higher for recipients of older cDCD grafts
(1.9% vs 6.9%; p = 0.004, Table 2). Logistic regression
model adjusted by recipient age and comorbidities
showed that recipient age was the only risk factor re-
lated to patient death, conferring a 11% excess risk for
mortality per each recipient’s year (OR 1.11 [1.04–1.19];
p = 0.002, Table 3).
Survival analyses (estimated by KM method) showed a
lower 1st-year-graft survival among those kidneys from
cDCD donors> 65 years (87.6% vs 96.2%; p = 0.02). How-
ever, death-censored graft survival was similar in both
groups (95.5% vs 98.25; p = 0.481) (Fig. 1). We per-
formed Cox regression and competing risk multivariate
analyses in order to analyze donor age impact on graft
survival. Adjusted-models did not show that donor age
itself and isolated was associated with graft survival but
eGFR< 30 ml/min at 1-year increased the risk eight -fold
(sHR 8.34 [2.82–24.65; p < 0.001, Table 4).
On the other hand, 1st-year patient survival was also
poorer (91.8% vs 97.9%; p= 0.01). Nine patients from the
group of older donors died with functioning graft during the
first year after transplantation (mostly in the first 6 months
after transplantation) due to cardiovascular events (n = 4),
sudden death of uncertain origin (n = 1), cancer (n = 1),
sepsis (n = 1), pulmonary embolism (n = 1), and unknown
cause (n = 1). Again, the multivariate analysis revealed that
only recipient age was as risk factor for patient survival, in-
creasing the risk around 10% per each recipient’s year of
age, both with Cox and competing risk analyses (Table 4).
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Table 1 Baseline characteristics among kidney transplant recipients from donors > 65 years and ≤ 65 years
Donor ≤65 years
(n = 426)
Donor > 65 years
(n = 135)
p-value
Recipient characteristics
Age (years, mean (SD)) 53.7 (11.4) 65.8 (8.8) < 0.001
Age > 65 years (%) 14.6 61.3 < 0.001
Female Gender (%) 30.1 35.6 0.23
Black Race (%) 1.4 0.7 0.5
Diabetes mellitus (%) 26.1 51.4 < 0.001
Previous cardiovascular eventa (%) 7.8 20.7 < 0.001
Cause of end-stage renal disease (%)
Hypertensive nephropathy 12.4 11.9
Diabetic nephropathy 11.3 22.2
Glomerulonephritis 19.0 12.6
Interstitial 11.0 11.9 0.03
Polycystic 15.3 11.1
Others 6.7 5.9
Unknown 19.7 23.7
Previous renal replacement therapy (%)
Hemodialysis 73.1 83.0
Peritoneal Dialysis 21.0 14.8 0.05
Preemptive kidney transplant 5.9 2.2
Dialysis vintage (years, median [IQR]) 1.1 [2.0–3.6] 1.3 [2.6–4.0] 0.08
Patients with previous kidney transplant (%) 8.4 7.4 0.7
Donor characteristics
Age (years, mean (SD)) 52.7 (9.1) 72.0 (4.9) < 0.001
Female Gender (%) 26.3 45.9 < 0.001
Expanded criteria donors (%) 29.3 100 < 0.001
Stroke as Cause of death (%) 49.2 67.8 < 0.001
Transplant characteristics
Number of HLA mismatches (median (IQR)) 4 [3–5] 4 [3–5] 0.003
Cold ischemia time (hours, median (IQR)) 11 [7–18] 9.5 [7–16.5] 0.326
Warm ischemia time (min, median (IQR)) 23.5 [15–36.5] 26 [16–35] 0.901
Induction treatment (Thymoglobulin, %) 70.7 57 0.003
Maintenance (Tacrolimus+MPA + steroids, %) 82.9 80.7 0.57
Time of follow-up (years, median [IQR]) 1.6 [0.9–2.6] 1.1 [0.7–1.8] < 0.001
SD standard deviation, MPA mycophenolic acid, IQR interquartile range
aAcute myocardial infarction, stroke or peripheral vascular disease (amputation)
Table 2 Patient and transplant outcomes among kidney transplant recipients from donors > 65 years and ≤ 65 years
Donor ≤65 years
(n = 426)
Donor > 65 years
(n = 135)
p-value
Early patient mortality (at first year, %) 1.9 6.9 0.004
Primary non-function (%) 3.1 3.7 0.71
Delayed graft function (%) 46.7 55.4 0.09
Acute rejection (%) 6.3 3.0 0.135
Creatinine at 12 month (mg/dl, mean (SD)) 1.51 (0.8) 1.60 (0.7) 0.29
eGFR at 12 month (ml/min, mean (SD)) 57.9 (24.7) 49.2 (20.0) < 0.001
eGFR estimated glomerular filtration rate calculated by MDRD-4
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Finally, we aimed to investigate which old donors
might carry a higher risk for the recipients, considering
early clinical outcomes. By adding classical donor car-
diovascular risk factors (serum creatinine > 1.5 mg/dl,
diabetes mellitus and cardiovascular as the cause of
death), we found that older donors with one or two of
those previous risk factors associated with significant
higher DGF rate (Table 5). Similar analyses for PNF,
poor kidney function (1st year eGFR < 30 ml/min) and
1st year mortality were not significant (data not shown).
Discussion
In this study, we present early clinical outcomes using
KT from cDCD older than 65 years. We found higher
1st year mortality among KT patients receiving a kidney
from an elderly donor, but it seems to be related to re-
cipient age. Donor age itself and isolated did not have
any impact on patient neither graft survival at short
term, although it was associated with poorer graft func-
tion in terms of eGFR.
As ECD-DCD donors may constitute more than 40%
of the total DCD donor pool in some centers [11], ef-
forts are targeted now to analyze outcomes using kid-
neys that come from those suboptimal donors. Some
reports have analyzed outcomes using ECD-DCD donors
in the US [1, 22, 23], Europe [7–11] and Japan [24].
Overall, results from ECD-DCD donors are poorer than
those obtained with standard-DCD donors, though not
inferior to ECD-DBD donors [1, 7, 9, 22, 24]. However,
these studies included KT recipients from classical ECD
defined by Organ Procurement Transplant Network
(OPTN, donors older than 60 years-old, or between 50
and 60 years-old with two of the following risk factors:
cardiovascular death, serum creatinine > 1.5mg/dl or
hypertension) but few studies have analyzed the results
with very elderly donors, i.e., older than 65 years-old [10].
Normally, studies have not been focused on patient
survival using expanded DCD donors, though we can
find a reported one-year-patient survival ranged from 85
to 91% among recipients who received kidneys from
ECD-DCD donors [7, 10, 23]. Two studies also com-
pared the mortality between those who underwent KT
from an ECD-DCD donor and those who remained
waitlisted on dialysis. They found that among older
recipients (> 65 years), there was no benefit in terms of
survival using kidneys from old DCD donors (> 65 years)
[10, 11], and younger recipients might have the potential
benefit of the expansion in DCD donor criteria accept-
ance [11]. In a recent observational study in patients
Table 3 Risk factors for relevant patient and allograft early
outcomes estimated with multivariate logistic regression analysis
OR 95% CI p-value
Primary non-function
Donor age > 65 years (vs ≤65 years) 2.50 [0.77–8.09] 0.128
Cold ischemia time > 17 h (vs shorter) 3.25 [1.02–10.33] 0.046
Delayed graft function
Donor age > 65 years (vs ≤65 years) 1.33 [0.87–2.03] 0.19
Dialysis vintage > 24months (vs shorter) 3.44 [2.39–4.94] < 0.001
eGFR< 30ml/min at month 12
Donor age > 65 years (vs ≤65 years) 1.15 [0.60–2.20] 0.427
Delayed graft function (vs immediate) 4.12 [2.07–8.22] < 0.001
Early patient mortality (first year)
Donor age > 65 year (vs ≤65 years) 1.37 [0.46–4.10] 0.578
Recipient age (per year) 1.11 [1.04–1.19] 0.002
OR odds ratio, CI confidence interval, eGFR estimated glomerular filtration rate
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Fig. 1 Kaplan-Meier survival curves between kidney transplant recipients from donors > 65 years and≤ 65 years. a Patient survival; b Graft survival;
c Death-censored graft survival
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older than 65 years old receiving an old kidney from
DCD donors over 65, Peter-Sengers et al. showed a 15%
higher mortality than we found among our recipients.
Although we have included recipients younger than 65
years old, our cohort included recipients of a special
high-risk profile, with a mean age near 66 years, high
prevalence of diabetes (> 50%) and previous cardiovas-
cular events (> 20%). When we analyzed the risk fac-
tors implicated in early patient survival, we confirmed
that only patient age was involved in patient prognosis
without any influence of donor age or donor comor-
bidity. These findings highlight the importance of a
carefully selection of the recipient, in order to avoid
early patient mortality.
In terms of graft survival, kidney grafts from ECD-
DCD donors have shown inferior survival than those
from standard DCD donors [1, 24], though similar to
ECD-DBD ones [7, 22]. One-year-graft survival has been
reported from 74 to 90% [7, 9, 23, 24], similar to ours,
despite our donors were almost 5 years older than those
from the study by Peter-Sengers et al. which reported
the oldest ones so far [10]. In fact, we found no
differences in 1st year death-censored-graft survival re-
gardless donor age, highlighting that differences observed
in non-censored graft survival are related to a higher rate
of patient mortality during the 1st year within recipients
who received a kidney from an older donor.
Disparities have been found in other outcomes such
as DGF or PNF. While the US Registry found no differ-
ences in terms of among ECD-DCD donors and non-
ECD-DCD donors, the UK cohort found a higher rate
of both PNF and DGF between older donors but com-
paring to donors younger than 40 years [7]. However,
an update of the UK Registry showed similar rates of
PNF and similar 5-year graft survival between ECD-
DCD and brain-dead ECD KT [8]. The study from the
Netherlands found a high-rate of both PNF (12.7%) and
DGF (74.1%) in recipients > 65y who received organs
from donors > 65 y [10]. Our PNF rate was similar
between the groups and below 4% and the only factor
that increased the risk was a prolonged cold ischemia
time, consistently with other authors’ findings [7]. In
our study, the incidence of DGF was high in both
groups, with a clear tendency of higher rate among re-
cipients from older donors. The multivariate analysis
showed that donor age itself was not associated with
higher rate of DGF, but if we considered high-risk
donor profile (older plus other comorbidities) the risk
is increased by three-fold.
Poorer kidney function has also been shown in kidneys
from ECD-DCD donors [7, 9]. In fact, two-thirds of old
recipients from DCD donors over 65 y presented with
eGFR< 30 ml/min at 1st year [10]. We did not find any
statistical difference in terms of serum creatinine at 1st
year after transplantation although kidney function was
poorer in recipients from elderly cDCD.
Table 4 Risk factors for relevant patient and allograft early outcomes estimated with Cox regression analysis (HR) and competing
risk analysis (sHR)
Risk factor HR 95% CI p-value sHR 95% CI p-value
Patient survival
Model 1 (raw) Donor age > 65y (vs ≤ 65 years) 2.94 [1.22–7.11] 0.016 3.17 [1.38–7.27] 0.015
Model 2 (adjusted by recipient age) Donor age > 65y (vs ≤ 65 years) 1.17 [0.44–3.08] 0.751 1.26 [0.48–3.34] 0.636
Recipient age 1.10 [1.04–1.16] 0.001 1.1 [1.05–1.16] < 0.001
Model 3 (adjusted by recipient age + previous CV event) Donor age > 65y (vs ≤ 65 years) 1.06 [0.40–2.82] 0.900 1.06 [0.36–3.12] 0.910
Recipient age 1.10 [1.04–1.16] 0.001 1.09 [1.04–1.15] < 0.001
Previous CV event 2.02 [0.76–5.36] 0.158 2.00 [0.73–5.47] 0.178
Death-censored graft survival
Model 1 (raw) Donor age > 65y (vs ≤ 65 years) 1.30 [0.47–3.60] 0.620 1.28 [0.47–3.47] 0.631
Model 2 (adjusted by recipient age) Donor age > 65y (vs ≤ 65 years) 1.17 [0.44–3.08] 0.751 1.00 [0.30–3.38] 0.997
Recipient age 1.10 [1.04–1.16] 0.001 1.02 [0.97–1.07] 0.425
Model 3 (adjusted by eGFR< 30 ml/min at first month) Donor age > 65y (vs ≤ 65 years) 0.66 0.15–3.01 0.595 0.58 [0.12–2.74] 0.487
eGFR< 30 ml/min at first month 8.70 2.99–25.25 < 0.001 8.34 2.82–24.65 < 0.001
HR hazard ratio, sHR sub-hazard ratio, CI confidence interval, eGFR estimated glomerular filtration rate, CV cardiovascular
Table 5 Risk factors for relevant renal allograft outcomes
estimated with logistic regression analysis
OR 95% CI p-value
Delayed graft function
Donor age > 65 years + 0 risk factor 1.32 0.79–2.22 0.30
Donor age > 65 years + 1 risk factor 1.79 1.05–3.05 0.03
Donor age > 65 years + 2 risk factors 3.84 1.91–7.72 < 0.001
Donor risk factors are defined as creatinine > 1.5 mg/dl, cardiovascular death
and hypertension. Similar analyses for Primary non function, estimated
glomerular filtration rate < 30 ml/min at 12 months and early patient mortality
were not significant
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Our study is limited by the sample size and the relative
short-term follow-up. However, we aimed to analyze 1st
year results using elderly cDCD in our media, to know
results and implement the proper strategy changes if
needed. In fact, this is the first study that analyzes out-
comes in an important number of elderly cDCD (mean
age 72 years) allocated to a high-risk recipient cohort.
We found a higher mortality compared to recipients
who received organs from younger donors. However, in
the multivariate model the recipient age accounted for
all the risk and the weight of the donor age over the
death risk disappeared. Three different multivariate stat-
istical models showed these results, which reflects their
consistency. On the other hand, short-term graft survival
was similar and donor age itself did not have any impact
in patient or graft outcomes.
Conclusions
Our results pointed at similar patient and KT short-term
outcomes regardless of donor age, which may suggest
better results than those previously reported. If these
findings were confirmed in long-term studies, they
might generate changes in acceptance and allocation of
these grafts for KT. In fact, when we added comorbidity
factors other than donors’ age, some outcomes as DGF
seem to be affected. Careful pre-transplant evaluation
should be performed in these extremely high-risk group
in order to improve outcomes, but kidneys from old
cDCD should not be discarded systematically.
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